Peptide synthesis has emerged as a pivotal methodology in bioorganic chemistry, propelling scientific progress to new heights. Recent advancements in chemistry and technology have revolutionized peptide synthesis methods, making them indispensable in biomedical research. Synthetic peptides have become essential tools for probing biological structures, developing enzyme inhibitors, and creating peptidomimetics as therapeutic agents. The remarkable efficacy, specificity, and low toxicity of peptides have captured the attention of pharmaceutical companies, resulting in FDA-approved peptide-based drugs entering the market. As a result, the global peptide synthesis market is poised for substantial growth.
Rising Use of Peptides in Pharmaceuticals and Research Activities Drive Market Growth
The increasing use of peptides in pharmaceutical treatments, heightened research endeavors supported by substantial R&D funding, and the development of advanced automated peptide synthesizers are key drivers propelling the growth of the peptide synthesis market. Peptide molecules have gained significant traction in the healthcare and nutrition sectors, with considerable advancements achieved in both enzymatic and chemical peptide production methods. The escalating research expenditures are opening doors for further expansion of the peptide synthesis market in the years ahead.
Abundance of FDA-Approved Drugs and a Robust Pipeline Boost Peptide Consumption
Peptides, known for their high activity and selectivity, find applications across various therapeutic areas due to their diverse biological actions. Their favorable attributes, including a broad chemical space, high specificity, simplicity of synthesis, and low toxicity, have accelerated their adoption in drug development. With over 100 FDA-approved peptide-based medications already available and more than 700 peptide medicines and therapeutic peptides in clinical trials or preclinical development, this figure is set to surge dramatically.
Peptides are in high demand for treating cardiovascular and neurological diseases, renal failure, and rare disorders, contributing to billions in revenue across primary therapeutic areas such as cancer, diabetes, and obesity. The escalating prevalence of cardiovascular disease is anticipated to drive demand for peptides, further boosting the prospects of the peptide synthesis market.
Reagents Continue to Dominate the Peptide Synthesis Market
The reagents segment is expected to maintain its dominance in the peptide synthesis market. This can be attributed to the growing applications of peptides in therapeutics, drug design, and gene synthesis, along with the frequent procurement of reagents over equipment. Additionally, the increasing number of ongoing research projects involving peptide synthesis and the availability of a wide range of peptide synthesis reagents contribute to the segments significant market share. High research and development investments by biotechnology companies, a rise in the number of biotechnology firms, and ongoing technological advancements are projected to drive the growth of the reagents segment in the forecast period.
North America Leads, Asia Pacific Shows Fastest Growth
North America holds the largest share in the global peptide synthesis market, driven by the presence of major market players, heightened awareness of accessible peptide synthesis methods, and a growing focus on commercializing peptide therapeutics. Increased research in life sciences, a high prevalence of chronic diseases, investments in structure-based drug design, and a strong emphasis on personalized therapeutics contribute to North Americas significant market share. The United States is expected to account for the most substantial proportion of the North American market due to increased life science research activities and the rising prevalence of diseases like cancer and diabetes.
Asia Pacific is anticipated to witness the fastest growth during the forecast period, driven by increased investments by market players, growing awareness of novel peptide treatments, rising healthcare spending by governments and patients, distribution collaborations between multinational companies and local players, and an upsurge in chronic diseases in low- and middle-income countries. The region is poised to capitalize on the awareness of innovative peptide therapeutics and increased healthcare expenditure in the coming years.
Global Peptide Synthesis Market: Competitive Landscape
Market participants are actively introducing new products and forming collaborations, alliances, and partnership agreements to stay competitive. Notable developments include GenScripts Neoantigen Specific Peptide Synthesis Service for precision immuno-oncology therapeutics and JPT Peptide Technologies release of ready-to-use peptide tools for investigating the immune response to SARS-CoV-2 infection.
Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2023-2030 By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa) https://www.fairfieldmarketresearch.com/report/peptide-synthesis-market
Our Blogs:
About Us
Fairfield Market Research is a UK-based market research provider. Fairfield offers a wide spectrum of
services, ranging from customized reports to consulting solutions. With a strong European footprint, Fairfield operates globally and helps businesses navigate through business cycles, with quick responses and multi-pronged approaches. The company values an eye for insightful take on global matters, ably backed by a team of exceptionally experienced researchers. With a strong repository of syndicated market research reports that are continuously published & updated to ensure the ever-changing needs of customers are met with absolute promptness.
Contact
Fairfield Market Research
London, UK
UK +44 (0)20 30025888
USA (Toll-free) +1 (844) 3829746
Web: https://www.fairfieldmarketresearch.com/
Email: sales@fairfieldmarketresearch.com
This press release first seen on Brilad
COMTEX_442085732/2840/2023-10-18T16:49:22
Julian Lopez is professor emeritus of finance, served as the founding academic affairs dean and founding chair of the finance department.
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No journalist was involved in the writing and production of this article.